Pill Identifier App

New Drug Approvals Archive

Get news by email or subscribe to our news feeds.

February 2004

February 4

Alimta (pemetrexed) Injection

Date of Approval: February 4, 2004
Company: Eli Lilly
Treatment for: Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer

Alimta (pemetrexed) is an antifolate antineoplastic agent indicated for the treatment of malignant pleural mesothelioma and locally-advanced and metastatic non-small cell lung cancer (NSCLC).

Alimta (pemetrexed) FDA Approval History

February 4

Orthovisc (sodium hyaluronate) Injection

Date of Approval: February 4, 2004
Company: Anika Therapeutics, Inc.
Treatment for: Osteoarthritis

Orthovisc is a highly purified, high molecular weight form of hyaluronic acid used for treating pain in patients suffering from osteoarthritis (OA) of the knee who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics.

Orthovisc (sodium hyaluronate) FDA Approval History

February 9

Fazaclo (clozapine) Orally Disintegrating Tablets

Date of Approval: February 9, 2004
Company: Alamo Pharmaceuticals
Treatment for: Schizophrenia

Fazaclo is an orally disintegrating atypical antipsychotic indicated for the treatment of schizophrenia.

Fazaclo (clozapine) FDA Approval History

February 9

EstroGel (estradiol topical) Gel

Date of Approval: February 9, 2004
Company: Solvay Pharmaceuticals
Treatment for: Postmenopausal Symptoms

EstroGel (estradiol) is transdermal gel estrogen therapy for the treatment of moderate to severe vasomotor symptoms, as well as vulvar and vaginal atrophy associated with the menopause.

EstroGel (estradiol topical) FDA Approval History

February 12

Rhophylac (Rh0(D) immune globulin intravenous (human)) Injection

Date of Approval: February 12, 2004
Company: ZLB Bioplasma AG, Switzerland
Treatment for: Prevention of Rho(D) Sensitization

Rhophylac (Rh0(D) immune globulin intravenous (human)) is indicated for the suppression of rhesus (Rh) isoimmunization in pregnancy, obstetric conditions and incompatible transfusions, and the treatment of immune thrombocytopenic purpura.

Rhophylac (Rh0(D) immune globulin intravenous (human)) FDA Approval History

February 12

Erbitux (cetuximab) Injection

Date of Approval: February 12, 2004
Company: ImClone
Treatment for: Colorectal Cancer, Head and Neck Cancer

Erbitux is epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of colorectal cancer and Head and Neck Cancer.

Erbitux (cetuximab) FDA Approval History

February 26

Avastin (bevacizumab) Injection

Date of Approval: February 26, 2004
Company: Genentech, Inc.
Treatment for: Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma

Avastin (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody for the treatment of metastatic colorectal cancer, non-small cell lung cancer, HER2-negative breast cancer, glioblastoma and renal cell carcinoma .

Avastin (bevacizumab) FDA Approval History

February 27

Myfortic (mycophenolic acid) Tablets

Date of Approval: February 27, 2004
Company: Novartis Pharma AG
Treatment for: Organ Transplant -- Rejection Prophylaxis

Myfortic is an enteric-coated formulation of mycophenolic acid for use in combination with cyclosporine and corticosteroids to prevent organ rejection in kidney transplant patients.

Myfortic (mycophenolic acid) FDA Approval History

October 11

Avastin (bevacizumab)

New Indication Approved: October 11, 2006

Avastin (bevacizumab) FDA Approval History

April 2

Rhophylac (Rh0(D) immune globulin intravenous (human))

New Indication Approved: March 16, 2007
Treatment for: Prevention of Rho(D) Sensitization

Rhophylac (Rh0(D) immune globulin intravenous (human)) FDA Approval History

February 25

Avastin (bevacizumab)

New Indication Approved: February 22, 2008

Avastin (bevacizumab) FDA Approval History

September 29

Alimta (pemetrexed)

New Indication Approved: September 26, 2008

Alimta (pemetrexed) FDA Approval History

May 6

Avastin (bevacizumab)

New Indication Approved: May 5, 2009

Avastin (bevacizumab) FDA Approval History

July 7

Alimta (pemetrexed)

New Indication Approved: July 2, 2009

Alimta (pemetrexed) FDA Approval History

August 3

Avastin (bevacizumab)

New Indication Approved: July 31, 2009

Avastin (bevacizumab) FDA Approval History

November 7

Erbitux (cetuximab)

New Indication Approved: November 7, 2011

Erbitux (cetuximab) FDA Approval History

Hide
(web5)